All In Biotech

Free tool

FAERS Monitor: Bilprevda

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761444 or its brand name (Bilprevda, Denosumab-Nxxp). Reports on generic versions are filed under their own applications.

Reports

16,625

Serious

15,968

96% of reports

Hospitalization

6,867

Death reported

1,943

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • osteonecrosis of jaw1,555
  • diarrhoea1,177
  • fatigue1,139
  • nausea1,088
  • malignant neoplasm progression1,072
  • neutropenia981
  • metastases to bone857
  • off label use847
  • anaemia758
  • vomiting619
  • dyspnoea609
  • hypocalcaemia608
  • decreased appetite606
  • drug ineffective554
  • pyrexia535

Reports by year received

View as table
YearReports
20081
20092
201067
2011136
2012214
2013358
2014474
2015662
2016748
2017636
2018956
20191,013
20201,063
20211,495
20221,772
20231,781
20241,728
20251,749
20261,770

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,534 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
osteonecrosis of jawSignal1,55584.880.7120,690
metastases to boneSignal85769.665.154,931
hypocalcaemiaSignal60842.038.823,507
malignant neoplasm progressionSignal1,07213.412.612,190
neutropeniaSignal9819.28.67,144
anaemiaSignal7585.04.72,466
decreased appetiteSignal6063.33.1981
diarrhoeaSignal1,1772.32.2898
pyrexia5352.01.8253
fatigue1,1391.91.8462
nausea1,0881.71.6355
vomiting6191.71.5168
dyspnoea6091.41.360
off label use8471.21.136
drug ineffective5540.50.5243

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.